LONDON, July 17 AstraZeneca is to
conduct a new global clinical trial of its heart drug Brilinta
involving 11,500 patients with peripheral artery disease,
Britain's second biggest drugmaker said on Tuesday.
Peripheral artery disease affects around 27 million people
in Europe and North America. Sufferers are at high risk of heart
attacks, strokes and other complications.
The new study will compare AstraZeneca's medicine, which is
currently only approved for patients with acute coronary
syndromes, against its older rival Plavix.